Anzeige
Mehr »
Login
Montag, 23.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 870513 | ISIN: US7493604000 | Ticker-Symbol:
NASDAQ
20.12.24
21:59 Uhr
21,500 US-Dollar
-0,180
-0,83 %
1-Jahres-Chart
RCM TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
RCM TECHNOLOGIES INC 5-Tage-Chart
GlobeNewswire (Europe)
37 Leser
Artikel bewerten:
(0)

RCM Technologies, Inc. Announces Third Quarter Results

Finanznachrichten News

PENNSAUKEN, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of solutions designed to enhance the operational performance of its customers through the deployment of advanced engineering, specialty health care, and information technology services, today announced financial results for the thirteen and thirty-nine weeks ended September 28, 2024.

RCM Technologies reported revenue of $60.4 million for the thirteen weeks ended September 28, 2024 (the current quarter), an increase of 4.0% compared to $58.0 million for the thirteen weeks ended September 30, 2023 (the comparable prior quarter). Gross profit was $17.8 million for the current quarter, a 3.2% increase compared to $17.3 million for the comparable prior quarter. The Company experienced GAAP net income of $2.7 million, or $0.35 per diluted share, for the current quarter compared to $3.8 million, or $0.46 per diluted share, for the comparable prior quarter. The Company experienced adjusted EBITDA (non-GAAP) of $5.6 million for the current quarter, a 9.5% increase compared to $5.1 million for the comparable prior quarter. The Company experienced $0.44 of adjusted net income per diluted share (non-GAAP) for the current quarter as compared to $0.50 for the comparable prior quarter.

RCM Technologies reported revenue of $201.5 million for the thirty-nine weeks ended September 28, 2024 (the current period), an increase of 4.8% compared to $192.2 million for the thirty-nine weeks ended September 30, 2023 (the comparable prior-year period). Gross profit was $58.2 million for the current period, a 5.7% increase compared to $55.1 million for the comparable prior-year period. The Company experienced GAAP net income of $10.5 million, or $1.31 per diluted share, for the current period compared to $11.6 million, or $1.33 per diluted share, for the comparable prior-year period. The Company experienced adjusted EBITDA (non-GAAP) of $19.6 million for the current period, a 10.5% increase compared to $17.7 million for the comparable prior-year period. The Company experienced $1.54 of adjusted net income per diluted share (non-GAAP) for the current period as compared to $1.41 for the comparable prior-year period.

Bradley Vizi, Executive Chairman of RCM Technologies, commented, "Third-quarter growth was led by Healthcare and Engineering, as both businesses continue to ramp in their respective end markets."

Kevin Miller, Chief Financial Officer of RCM Technologies, commented, "Growth remains consistent, while we anticipate enhanced cash conversion in coming quarters."

Conference Call
On Friday, November 8, 2024, RCM Technologies will host a conference call to discuss these results. The call will begin at 1:00 p.m. Eastern Time. The dial-in number is (888) 272-8703.

About RCM
RCM Technologies (NasdaqGM: RCMT) is a business and technology solutions provider with world-class talent in key market segments. We help design, build, and enable the Industries of Tomorrow, Today. Operating at the intersection of resources, critical infrastructure and modernization of industries, RCM is a provider of services in Health Care, Engineering, Aerospace & Defense, Process & Industrial, Life Sciences and Data & Solutions. www.rcmt.com.

The statements contained in this release that are not purely historical are forward-looking statements within the Private Securities Litigation Reform Act of 1995. They are subject to various risks, uncertainties, and other factors that could cause the Company's actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should," "are confident" or similar expressions. In addition, statements that are not historical should also be considered forward-looking statements. These statements are based on assumptions that we have made in light of our experience in the industry, and our perceptions of historical trends, current conditions, expected future developments, and other factors we believe are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to demand for the Company's services, expectations regarding our future revenues and other financial results, such as cash flows, our pipeline, and potential project wins, and our expectations for investment and growth in our business. Such statements are based on current expectations that involve several known and unknown risks, uncertainties, and other factors, which may cause actual events to be materially different from those expressed or implied by such forward-looking statements. Risk, uncertainties, and other factors may emerge from time to time that could cause the Company's actual results to differ from those indicated by the forward-looking statements. Investors are directed to consider such risks, uncertainties, and other factors described in documents filed by the Company with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company assumes no obligation (and expressly disclaims any such obligation) to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.

Tables to Follow
RCM Technologies, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In Thousands, Except Per Share Amounts)

Thirteen Weeks Ended
September 28,
2024
September 30,
2023
Revenue $60,365 $58,049
Cost of services 42,524 40,768
Gross profit 17,841 17,281
Selling, general and administrative 13,018 12,662
Depreciation and amortization of property and equipment 393 243
Amortization of acquired intangible assets 45 45
Operating income 4,385 4,331
Other expense, net 619 141
Income before income taxes 3,766 4,190
Income tax expense 1,020 434
Net income $2,746 $3,756
Diluted net earnings per share data $0.35 $0.46
Diluted weighted average shares outstanding 7,789,446 8,196,330
Thirty-Nine Weeks Ended
September 28,
2024
September 30,
2023
Revenue $201,468 $192,209
Cost of services 143,259 137,144
Gross profit 58,209 55,065
Selling, general and administrative 40,762 38,782
Depreciation and amortization of property and equipment 1,012 756
Amortization of acquired intangible assets 136 136
Costs associated with potential stock issuance 259 -
Gain on sale of assets - (395)
Operating income 16,040 15,786
Other expense, net 1,619 965
Income before income taxes 14,421 14,821
Income tax expense 3,961 3,245
Net income $10,460 $11,576
Diluted net earnings per share data $1.31 $1.33
Diluted weighted average shares outstanding 7,990,238 8,730,998
RCM Technologies, Inc.
Supplemental Operating Results on a Non-GAAP Basis
(Unaudited)
(In Thousands)


The following non-GAAP measures, which adjust for the categories of expenses described below, are non-GAAP financial measures. Our management believes that these non-GAAP financial measures ("Adjusted operating income," "EBITDA," "Adjusted EBITDA," "Adjusted net income" and "Adjusted diluted net earnings per share") are useful information for investors, shareholders, and other stakeholders of our Company in gauging our results of operations on an ongoing basis and to enhance investors' overall understanding of our current financial performance and period-to-period comparisons. Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share should not be considered alternatives to operating income or net income, as the case may be, as an indicator of performance. In addition, Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share do not take into account changes in certain assets and liabilities and interest and income taxes that can affect cash flows. We do not intend the presentation of these non-GAAP measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP. These non-GAAP measures should be read-only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

The following unaudited table presents the Company's GAAP operating income and GAAP net income and the corresponding adjustments used to calculate Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share for the thirteen and thirty-nine weeks ended September 28, 2024 and September 30, 2023.

Thirteen Weeks Ended Thirty-Nine Weeks Ended
September 28,
2024
September 30,
2023
September 28,
2024
September 30,
2023
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
GAAP operating income $4,385 $4,331 $16,040 $15,786
Adjustments
Gain on sale of assets - - - (395)
Costs associated with potential stock issuance - - 259 -
Equity compensation 767 484 2,154 1,451
Adjusted operating income (non-GAAP) $5,152 $4,815 $18,453 $16,842
GAAP net income $2,746 $3,756 $10,460 $11,576
Income tax expense 1,020 434 3,961 3,245
Interest expense, net 492 185 1,551 970
Depreciation of property and equipment 393 243 1,012 756
Amortization of acquired intangible assets 45 45 136 136
EBITDA (non-GAAP) $4,696 $4,663 $17,120 $16,683
Adjustments
Gain on sale of assets - - - (395)
Costs associated with potential stock issuance - - 259 -
Loss (gain) on foreign currency transactions 127 (44) 68 (5)
Equity compensation 767 484 2,154 1,451
Adjusted EBITDA (non-GAAP) $5,590 $5,103 $19,601 $17,734
RCM Technologies, Inc.
Supplemental Operating Results on a Non-GAAP Basis (Continued)
(Unaudited)
(In Thousands)

Thirteen Weeks Ended Thirty-Nine Weeks Ended
September 28,
2024
September 30,
2023
September 28,
2024
September 30,
2023
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
GAAP net income $2,746 $3,756 $10,460 $11,576
Adjustments
Gain on sale of assets - - - (395)
Costs associated with potential stock issuance - - 259 -
Loss (gain) on foreign currency transactions 127 (44) 68 (5)
Equity compensation 767 484 2,154 1,451
Tax impact from normalized rate (190) (138) (674) (295)
Adjusted net income (non-GAAP) $3,450 $4,058 $12,267 $12,332
GAAP diluted net earnings per share $0.35 $0.46 $1.31 $1.33
Adjustments
Gain on sale of assets ($0.04)
Costs associated with potential stock issuance - - $0.03 -
Loss (gain) on foreign currency transactions $0.01 - $0.01 -
Equity compensation $0.10 $0.06 $0.27 $0.16
Tax impact from normalized rate ($0.02) ($0.02) ($0.08) ($0.04)
Adjusted diluted net earnings per share (non-GAAP) $0.44 $0.50 $1.54 $1.41
RCM Technologies, Inc.
Summary of Selected Income Statement Data
(Unaudited)
(In Thousands)

Thirteen Weeks Ended September 28, 2024
Specialty
Health Care
Engineering Life Sciences
and IT
Consolidated
Revenue $26,554 $24,167 $9,644 $60,365
Cost of services 18,271 18,273 5,980 42,524
Gross profit 8,283 5,894 3,664 17,841
Gross profit margin 31.2% 24.4% 38.0% 29.6%
Thirteen Weeks Ended September 30, 2023
Specialty
Health Care
Engineering Life Sciences
and IT
Consolidated
Revenue $24,895 $22,452 $10,702 $58,049
Cost of services 17,438 16,846 6,484 40,768
Gross profit $7,457 $5,606 $4,218 $17,281
Gross profit margin 30.0% 25.0% 39.4% 29.8%
Thirty-Nine Weeks Ended September 28, 2024
Specialty
Health Care
Engineering Life Sciences
and IT
Consolidated
Revenue $101,668 $70,180 $29,620 $201,468
Cost of services 71,672 52,818 18,769 143,259
Gross profit 29,996 17,362 10,851 58,209
Gross profit margin 29.5% 24.7% 36.6% 28.9%
Thirty-Nine Weeks Ended September 30, 2023
Specialty
Health Care
Engineering Life Sciences
and IT
Consolidated
Revenue $99,553 $61,956 $30,700 $192,209
Cost of services 70,623 47,482 19,039 137,144
Gross profit $28,930 $14,474 $11,661 $55,065
Gross profit margin 29.1% 23.4% 38.0% 28.6%
RCM Technologies, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In Thousands, Except Share Amounts)

September 28, December 30,
2024 2023
(Unaudited)
Current assets:
Cash and cash equivalents $3,156 $6,284
Accounts receivable, net of provision for credit losses of $1,600 at September 28, 2024 and December 30, 2023 75,913 70,690
Transit accounts receivable 6,315 8,891
Prepaid expenses and other current assets 5,112 4,637
Total current assets 90,496 90,502
Property and equipment, net 6,793 4,005
Deposits 215 313
Deferred income taxes, foreign 55 55
Goodwill 22,147 22,147
Operating right of use asset 5,292 2,779
Intangible assets, net 547 683
Total other assets 28,256 25,977
Total assets $125,545 $120,484
Current liabilities:
Accounts payable and accrued expenses $11,525 $12,454
Transit accounts payable 28,215 31,102
Accrued payroll and related costs 11,634 11,203
Finance lease payable 689 233
Income taxes payable 220 330
Operating right of use liability 1,019 693
Contingent consideration from acquisitions 300 300
Deferred revenue 2,042 1,881
Total current liabilities 55,644 58,196
Deferred income taxes, net, foreign 185 187
Deferred income taxes, net, domestic 1,719 1,568
Finance lease payable, net of current position 1,290 -
Contingent consideration from acquisitions, net of current position 1,671 1,671
Operating right of use liability, net of current position 4,519 2,268
Borrowings under line of credit 30,477 30,804
Total liabilities 95,505 94,694
Contingencies (note 15) - -
Stockholders' equity:
Preferred stock, $1.00 par value; 5,000,000 shares authorized; no shares issued or outstanding - -
Common stock, $0.05 par value; 40,000,000 shares authorized; 17,833,287 shares issued and 7,597,028 shares outstanding at September 28, 2024 and 17,673,427 shares issued and 7,844,821 shares outstanding at December 30, 2023 890 882
Additional paid-in capital 118,136 116,579
Accumulated other comprehensive loss (2,787) (2,813)
Accumulated deficit (8,805) (19,265)
Treasury stock, 10,236,259 shares at September 28, 2024 and 9,828,606 shares at December 30, 2023, at cost (77,394) (69,593)
Total stockholders' equity 30,040 25,790
Total liabilities and stockholders' equity $125,545 $120,484
RCM Technologies, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In Thousands)

Thirteen Weeks Ended
September 28,
2024
September 30,
2023
Net income $2,746 $3,756
Adjustments to reconcile net income to cash used in operating activities 1,508 1,049
Changes in operating assets and liabilities:
Accounts receivable (9,033) 4,143
Prepaid expenses and other current assets 321 (987)
Net of transit accounts receivable and payable 435 1,556
Accounts payable and accrued expenses (1,445) (785)
Accrued payroll and related costs 1,919 2,790
Right of use liabilities (228) (333)
Income taxes payable 81 15
Deferred revenue (636) (169)
Deposits (12) 2
Total adjustments (7,090) 7,281
Net cash (used in) provided by operating activities ($4,344) $11,037
Net cash (used in) provided by investing activities (522) 79
Net cash provided by (used in) financing activities 4,375 (11,343)
Effect of exchange rate changes on cash and cash equivalents 167 (392)
Decrease in cash and cash equivalents ($324) ($619)
Common stock repurchase ($2,410) ($3,389)
Thirty-Nine Weeks Ended
September 28,
2024
September 30,
2023
Net income $10,460 $11,576
Adjustments to reconcile net income to cash used in operating activities 4,200 2,795
Changes in operating assets and liabilities:
Accounts receivable (5,207) (6,696)
Prepaid expenses and other current assets (475) (675)
Net of transit accounts receivable and payable (311) 22,384
Accounts payable and accrued expenses (760) (1,798)
Accrued payroll and related costs 433 1,596
Right of use liabilities (686) (1,016)
Income taxes payable (106) 162
Deferred revenue 161 (784)
Deposits 98 4
Total adjustments (2,653) 15,972
Net cash provided by operating activities 7,807 27,548
Net cash used in investing activities (1,589) (480)
Net cash used in financing activities (9,135) (26,558)
Effect of exchange rate changes on cash and cash equivalents (211) (195)
(Decrease) increase in cash and cash equivalents ($3,128) $315
Common stock repurchase ($7,801) ($24,449)
RCM Technologies, Inc.Tel: 856.356.4500Corporate Contacts:
2500 McClellan Avenueinfo@rcmt.comBradley S. Vizi
Pennsauken, NJ 08109www.rcmt.comExecutive Chairman
Kevin D. Miller
Chief Financial Officer

© 2024 GlobeNewswire (Europe)
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.